Key points are not available for this paper at this time.
The regimen of nab-paclitaxel plus gemcitabine has tolerable adverse effects with substantial antitumor activity, warranting phase III evaluation.
Share your take
Add a clinician perspective alongside expert commentary.
Hoff et al. (2011) studied this question.